Home Blogs
Sections
Forensic and Law Enforcement Drug Screening Harm Reduction
The newest version of BTNX Medetomidine Test Strip (Medetomidine 2.0 Test) detects both Medetomidine and Dexmedetomidine for more robust drug checking.
Introduction

Medetomidine, originally developed and introduced to the veterinary market in the late 1980s, is primarily used as a sedative, analgesic, and pre-anesthetic medication for animals. As an alpha-2 adrenergic agonist, it effectively induces sedation, muscle relaxation, and pain relief in various animal species, making it a valuable tool in veterinary procedures. Despite its intended use, the drug has occasionally found its way into illicit markets.

Dexmedetomidine, initially developed for human medical use in the 1990s, is widely utilized as a sedative and analgesic in clinical settings. As a highly selective alpha-2 adrenergic agonist, it provides sedation, pain relief, and anxiolysis, making it ideal for intensive care and surgical procedures. Its ability to maintain respiratory stability enhances its value in anesthesia and critical care. Levomedetomidine, the inactive enantiomer of medetomidine, exhibits significantly lower affinity for alpha-2 receptors and lacks comparable clinical efficacy. While dexmedetomidine is used in human pharmaceuticals, veterinary formulations commonly contain a racemic mixture of both isomers.

When dexmedetomidine misused recreationally, it can produce profound sedation, a sense of relaxation, and reduced anxiety, which appeal to individuals seeking intense sedative effects. However, its potent pharmacological properties pose significant health risks, including severe bradycardia (slowed heart rate), hypotension (low blood pressure), and respiratory depression. These effects are highly unpredictable and can be life-threatening, especially when combined with other central nervous system depressants like alcohol or opioids.

To address concerns about the illicit use of medetomidine, the Rapid Response® Medetomidine Test Strip (MED-18S2-100) from BTNX has been developed for efficient screening of Medetomidine in liquid or powder samples by using dexmedetomidine as the calibrator. This test utilizes a selective antibody to detect the presence of dexmedetomidine. Like other harm reduction test strips, it operates on a competitive binding principle: if the target is present in the sample at a concentration exceeding the cut-off, a single-colored line will appear in the test region.

Positive - Medetomidine Detected

Only one colored line appears in the control region (C). No apparent colored line appears in the test region (T).


Negative – Medetomidine Could Not be Detected

Two colored lines appear on the membrane. One line appears in the control region (C) and another line appears in the test region (T). Even faint lines are considered negative. All negative results are presumptive. Confirmation should be performed using GC-MS or LC-MS analysis. There is still a risk of overdose, even if dexmedetomidine is not present in your drugs. 


Test Performance – What makes us different?

Sensitivity

The following compounds were individually spiked into water to evaluate the detection capability of the Rapid Response® Medetomidine Test Strip. The cut-off listed in the table represents the concentration at which a substance will begin to show a mix of positive and negative results.

Compounds Cut off
Dexmedetomidine 1000 ng/mL
Medetomidine (racemic) 1500 ng/mL
 

Specificity

IMPORTANT NOTE: THE TEST CROSS REACTS WITH DETOMIDINE AT 20 µG/ML. 
Detomidine and medetomidine are both α2-adrenergic agonists commonly used in veterinary medicine. They are chemically related and share similar pharmacological properties.

The following compounds were spiked into water, respectively, to examine possible cross-reactivity. No false positive was observed at the concentration listed below. 

Compounds Concentration
Quinine 5 mg/mL
Levamisole 2 mg/mL
Caffeine 5 mg/mL
Lidocaine 5 mg/mL
Diphenhydramine 5 mg/mL
Xylazine 5 mg/mL
Codeine 5 mg/mL
Heroin (Diamorphine Hydrochloride) 5 mg/mL
Methamphetamine 5 mg/mL
MDMA 2 mg/mL
Acetaminophen 5 mg/mL
Morphine 5 mg/mL
Tramadol 5 mg/mL
Ketamine 5 mg/mL
Cocaine 5 mg/mL
Oxycodone 5 mg/mL
Methadone 5 mg/mL
Meperidine 5 mg/mL
 

Third-Party Evaluations

Isomeric Determination of Medetomidine in Street Drug Samples (August 2024 – February 2025) and Implications for Immunoassay Test Strip Analysis

The study by the National Institute of Standards and Technology (NIST) examined the presence and isomeric composition of medetomidine in 100 illicit drug samples collected between August 2024 and February 2025 across five East Coast U.S. states. Medetomidine exists as mixture of the two optical isomers: dexmedetomidine (active) and levomedetomidine (inactive in humans). The study also evaluated the utility and limitations of BTNX’s immunoassay-based medetomidine test strip in detecting racemic mixtures in complex street drug samples.

Test Sensitivity

The BTNX medetomidine immunoassay test strips demonstrated clear differences in sensitivity across the medetomidine isomers. Dexmedetomidine, the pharmacologically active isomer, was consistently detected with an approximate limit of detection (LOD) of 1 µg/mL, showing stable positive results across replicates. Racemic medetomidine mixtures, which reflect the composition of most street drug samples, were detected at a slightly higher threshold with an LOD between 1 to 10 µg/mL. In contrast, levomedetomidine alone did not produce consistent positive results at any concentration tested, indicating minimal sensitivity to this inactive isomer. Overall, the strips exhibit sufficient sensitivity to detect the concentrations of dexmedetomidine and racemic mixtures expected in real-world samples, aligning well with their intended harm-reduction application.

 
 

Test Specificity

A comprehensive cross-reactivity panel of 77 compounds was evaluated, including common opioids (such as fentanyl, acetylfentanyl, heroin, methadone, oxycodone, sufentanil, and remifentanil), other α2-agonists and anesthetics (including xylazine, lidocaine, tetracaine, procaine, cocaine, quinine, and diphenhydramine), as well as other drugs and adulterants frequently encountered in street samples (such as methamphetamine, MDMA, benzodiazepines, cannabinoids including Δ-8 THC and Δ-9 THC, caffeine, and acetaminophen). No cross-reactivity was observed with any of these analytes, and positive results occurred only with medetomidine standards (dexmedetomidine and racemic mixtures), confirming the high specificity of the BTNX test strips.
 

Analyte

Concentration

Replicate 1

Replicate 2

Medetomidine (Dex + Levo)

1 mg/mL

Positive

Positive

Medetomidine (Dex)

1 mg/mL

Positive

Positive

Medetomidine (Levo)

1 mg/mL

Negative

Negative

Water

N/A

Negative

Negative

2C-B • HCl

1 mg/mL

Negative

Negative

4-ANPP

0.5 mg/mL

Negative

Negative

3,4-MDA

1 mg/mL

Negative

Negative

3,4-MDMA

1 mg/mL

Negative

Negative

6-Acetylmorphine

1 mg/mL

Negative

Negative

Acetaminophen

1 mg/mL

Negative

Negative

Acetyl Fentanyl• HCl

1 mg/mL

Negative

Negative

Alprazolam

1 mg/mL

Negative

Negative

Amphetamine

1 mg/mL

Negative

Negative

Aniline• HCl

1 mg/mL

Negative

Negative

Aspirin

1 mg/mL

Negative

Negative

Benzocaine

1 mg/mL

Negative

Negative

Benzoylecgonine

1 mg/mL

Negative

Negative

Bromazolam

1 mg/mL

Negative

Negative

BTMPS

1 mg/mL

Negative

Negative

Buprenorphine • HCl

1 mg/mL

Negative

Negative

Bupropion

1 mg/mL

Negative

Negative

Caffeine

1 mg/mL

Negative

Negative

Cocaine

1 mg/mL

Negative

Negative

Codeine

1 mg/mL

Negative

Negative

Deschloroketamine • HCl

1 mg/mL

Negative

Negative

Dextromethorphan

0.5 mg/mL

 

 

Diazepam

1 mg/mL

Negative

Negative

Dimethylsulfone

1 mg/mL

Negative

Negative

Diphenhydramine • HCl

1 mg/mL

Negative

Negative

Ephedrine • HCl

1 mg/mL

Negative

Negative

Etizolam

1 mg/mL

Negative

Negative

Etomidate

1 mg/mL

Negative

Negative

Eutylone

1 mg/mL

Negative

Negative

Fentanyl • C6H8O7

1 mg/mL

Negative

Negative

Flubromazepam

1 mg/mL

Negative

Negative

p-Fluorofentanyl

0.5 mg/mL

Negative

Negative

Gabapentin

1 mg/mL

Negative

Negative

Guaifenesin

1 mg/mL

Negative

Negative

Heroin

0.5 mg/mL

Negative

Negative

Hydroxyzine

1 mg/mL

Negative

Negative

Ibuprofen

1 mg/mL

Negative

Negative

Ketamine

0.5 mg/mL

Negative

Negative

Lactose

1 mg/mL

Negative

Negative

Levamisole

1 mg/mL

Negative

Negative

Lidocaine

1 mg/mL

Negative

Negative

Lisdexamfetamine • 2CH4SO3

1 mg/mL

Negative

Negative

LSD

0.5 mg/mL

Negative

Negative

Mannitol

1 mg/mL

Negative

Negative

Melatonin

1 mg/mL

Negative

Negative

Methamphetamine

1 mg/mL

Negative

Negative

Methadone

1 mg/mL

Negative

Negative

o-Methylfentanyl • HCl

0.1 mg/mL

Negative

Negative

Methylphenidate • HCl

1 mg/mL

Negative

Negative

Metonitazene

1 mg/mL

Negative

Negative

Naloxone • HCl

1 mg/mL

Negative

Negative

Nicotine

1 mg/mL

Negative

Negative

Noscapine

1 mg/mL

Negative

Negative

N-Piperidinyl Etonitazene

0.5 mg/mL

Negative

Negative

Oxycodone

0.5 mg/mL

Negative

Negative

Papaverine • HCl

1 mg/mL

Negative

Negative

Phencyclidine • HCl

1 mg/mL

Negative

Negative

Pentobarbital

0.5 mg/mL

Negative

Negative

Phenacetin

1 mg/mL

Negative

Negative

Phenethyl 4-ANPP

0.5 mg/mL

Negative

Negative

Phentermine

1 mg/mL

Negative

Negative

Phenylephrine

1 mg/mL

Negative

Negative

Piracetam

1 mg/mL

Negative

Negative

Procaine

1 mg/mL

Negative

Negative

Protonitazene

1 mg/mL

Negative

Negative

Quetiapine • ½C4H4O4

1 mg/mL

Negative

Negative

Quinine

1 mg/mL

Negative

Negative

Remifentanil • HCl

0.5 mg/mL

Negative

Negative

Sorbitol

1 mg/mL

Negative

Negative

Sufentanil • C6H8O7

0.5 mg/mL

Negative

Negative

Theobromine

1 mg/mL

Negative

Negative

Tramadol • HCl

0.5 mg/mL

Negative

Negative

Xylazine

1 mg/mL

Negative

Negative

Zolpidem

0.5 mg/mL

Negative

Negative

∆-8 THC

0.5 mg/mL

Negative

Negative

∆-9 THC

0.5 mg/mL

Negative

Negative

 

Results obtained using street drug samples (August 2024 – February 2025): 

From August 2024 to February 2025, medetomidine was found in one hundred samples street samples. 25 of the samples were tested using BTNX Dexmedetomidine Test Strip, and the strip successfully detected dexmedetomidine in all of them, yielding an overall sensitivity of 100%.

Sample #

Date Collected

Site #

Sample Type

Peak Area Ratio Dex/Levo (a.u.)

Test Strip Results*

Other Compounds in Sample

11

08/2024

4

Drug Product

1.10

Positive

Fentanyl; Tetracaine

12

08/2024

4

Drug Product

1.04

Positive

Fentanyl; Tetracaine

17

08/2024

2

Baggie Residue

0.93

Positive

Acetyl Fentanyl; Caffeine; Fentanyl; Tetracaine

41

11/2024

3

Unknown

0.66

Positive

BTMPS; Lidocaine

42

11/2024

3

Unknown

0.96

Positive

Caffeine; Fentanyl; Tetracaine

44

11/2024

1

Unknown

0.98

Positive

4-ANPP; Fentanyl; Xylazine

45

11/2024

1

Unknown

0.92

Positive

BTMPS; Fentanyl; Lidocaine; Tetracaine

49

12/2024

3

Unknown

0.94

Positive

4-ANPP; Acetaminophen; Fentanyl; Lidocaine; Tetracaine; Xylazine

51

01/2025

3

Unknown

0.94

Positive

4-ANPP; Fentanyl; Lidocaine; Tetracaine

56

01/2025

2

Syringe Residue

0.80

Positive

4-ANPP; Fentanyl; Lidocaine, Procaine

57

08/2024

4

Drug Product

1.05

Positive

BTMPS; Caffeine; Fentanyl; Lidocaine; Tetracaine

 

 

58

08/2024

4

Drug Product

1.06

Positive

Fentanyl; Procaine; Tetracaine; Xylazine

59

08/2024

4

Drug Product

1.09

Positive

Fentanyl; Lidocaine; Tetracaine

60

09/2024

4

Drug Product

1.04

Positive

Acetaminophen; Fentanyl; Fluorofentanyl

61

09/2024

4

Drug Product

0.98

Positive

Fentanyl; Lidocaine

62

09/2024

4

Drug Product

1.03

Positive

Fentanyl; Xylazine

63

09/2024

4

Drug Product

1.06

Positive

4-ANPP; Fentanyl; Xylazine

64

11/2024

4

Drug Product

1.03

Positive

4-ANPP; Fentanyl; Lidocaine

65

01/2025

4

Drug Product

0.99

Positive

BTMPS; Caffeine; Fentanyl; Lidocaine; Procaine; Tetracaine; Xylazine

66

01/2025

4

Drug Product

0.98

Positive

Caffeine; Lidocaine; Procaine; Tetracaine; Xylazine

70

12/2024

2

Baggie Residue

1.04

Positive

Fentanyl; Tetracaine

84

11/2024

2

Baggie Residue

0.79

Positive

4-ANPP; Acetaminophen; Fentanyl; Lidocaine; Tetracaine; Xylazine

86

11/2024

2

Baggie Residue

1.01

Positive

Fentanyl; Tetracaine

88

12/2024

2

Unknown

0.94

Positive

Etomidate; Fentanyl; Lidocaine; Tetracaine

93

01/2025

2

Baggie Residue

0.96

Positive

4-ANPP; Fentanyl; Xylazine

About Rapid Response® Medetomidine Test Strip

The test strip can be used for drug checking purposes but provides only qualitative, presumptive results of the presence of medetomidine in drug samples. The Rapid Response® Medetomidine Test Strip is a rapid test for the detection of medetomidine in liquid or powder substances. This test can detect other related compounds including dexmedetomidine. It is for forensic use only and is not an IVD.

Each test kit comes with individually sealed test strips in pouches for easy distribution and transportation. Our test strips also come with microscoops for a more convenient and accurate testing process. A result interpretation card is also included as a guide for reading the results where users can align and match the test strip with the illustration on the card. QR codes to external resources are printed on every packaging for a user-friendly experience.

Learn more about the test. Visit the product page.

Watch a video demonstration

Ordering Information

Rapid Response® Medetomidine Test Strip (Liquid / Powder) is available to purchase under the product code MED-18S2-100 from Lochness Medical Supplies in the USA and BTNX Inc. in Canada and the international market.

References
  1. Sisco, E., Ventura, M., & Shuda, S. A. (2025). Isomeric determination of medetomidine in street drug samples (August 2024 – February 2025) and implications for immunoassay test strip analysis. National Institute of Standards and Technology. https://doi.org/10.26434/chemrxiv-2025-f4s1s